Display options
Cite
Tostar U, Toftgård R, Zaphiropoulos PG, et al. Reduction of human embryonal rhabdomyosarcoma tumor growth by inhibition of the hedgehog signaling pathway. Genes Cancer. 2010;1(9):941-51doi: 10.1177/1947601910385449.
Tostar, U., Toftgård, R., Zaphiropoulos, P. G., & Shimokawa, T. (2010). Reduction of human embryonal rhabdomyosarcoma tumor growth by inhibition of the hedgehog signaling pathway. Genes & cancer, 1(9), 941-51. https://doi.org/10.1177/1947601910385449
Tostar, Ulrica, et al. "Reduction of human embryonal rhabdomyosarcoma tumor growth by inhibition of the hedgehog signaling pathway." Genes & cancer vol. 1,9 (2010): 941-51. doi: https://doi.org/10.1177/1947601910385449
Tostar U, Toftgård R, Zaphiropoulos PG, Shimokawa T. Reduction of human embryonal rhabdomyosarcoma tumor growth by inhibition of the hedgehog signaling pathway. Genes Cancer. 2010 Sep;1(9):941-51. doi: 10.1177/1947601910385449. PMID: 21779473; PMCID: PMC3092259.
Copy Download .nbib Format: NLM
Share it on

Genes Cancer. 2010 Sep;1(9):941-51. doi: 10.1177/1947601910385449.

Reduction of human embryonal rhabdomyosarcoma tumor growth by inhibition of the hedgehog signaling pathway.

Genes & cancer

Ulrica Tostar, Rune Toftgård, Peter G Zaphiropoulos, Takashi Shimokawa

Affiliations

  1. Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, SE-14183 Sweden.

PMID: 21779473 PMCID: PMC3092259 DOI: 10.1177/1947601910385449

Abstract

Rhabdomyosarcoma (RMS) is the most frequent soft-tissue sarcoma in children. Embryonal rhabdomyosarcoma (E-RMS) represents the most common RMS subtype, but the molecular events driving this tumor are still largely unknown. The hedgehog (HH) pathway, a major signal transduction cascade, is linked with many cancers, including RMS. As we previously have detected loss of heterozygosity of PTCH1 in E-RMS, we now examined 8 E-RMS tumor samples and 5 E-RMS cell lines for the presence of PTCH1 mutations, but none was detected. However, in the E-RMS cell lines, a variable pattern of up-regulated expression of certain HH signaling target genes, including HHIP, PTCH1, SFRP1, and GLI1, was observed. Moreover, treatment with the small molecule HH signaling inhibitors cyclopamine and GANT61 inhibited cell proliferation in all E-RMS cell lines analyzed. Interestingly, GANT61 was more effective, and this was accompanied by increased apoptosis, while cyclopamine promoted necrotic events. Specific knockdown of SMO had no effect on the proliferation of E-RMS cells, indicating the presence of an SMO-independent HH signaling pathway in the E-RMS cell lines. Furthermore, in an in vivo xenograft model, tumor growth was significantly reduced by GANT61 treatment of E-RMS cells. Additionally, siRNA experiments provided evidence that inhibition of GLI1 or GLI3 but not GLI2 was sufficient to reduce proliferation of these cell lines. As GANT61 is known to block GLI1/GLI2 transcriptional activity, the inhibition of E-RMS growth by GANT61 is likely to be mediated through GLI1. In conclusion, our findings implicate that GLI1 could constitute an effective therapeutic target in pediatric E-RMS.

Keywords: GANT; GLI; embryonal rhabdomyosarcoma; hedgehog signaling

References

  1. Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1643-8 - PubMed
  2. Cell. 1994 Dec 30;79(7):1157-64 - PubMed
  3. Cytogenet Cell Genet. 2001;95(3-4):134-42 - PubMed
  4. Genes Dev. 2002 Nov 1;16(21):2743-8 - PubMed
  5. Development. 2000 Apr;127(8):1593-605 - PubMed
  6. Development. 1999 Sep;126(17):3915-24 - PubMed
  7. J Biol Chem. 2009 Apr 3;284(14):9074-82 - PubMed
  8. Anticancer Res. 1989 Nov-Dec;9(6):1943-9 - PubMed
  9. Oncogene. 2008 May 22;27(23):3282-91 - PubMed
  10. Mol Carcinog. 2009 May;48(5):408-19 - PubMed
  11. Br J Cancer. 1986 Jul;54(1):83-90 - PubMed
  12. PLoS One. 2009 Oct 27;4(10):e7608 - PubMed
  13. Proc Natl Acad Sci U S A. 2007 May 15;104(20):8455-60 - PubMed
  14. Oncogene. 2007 Jul 26;26(34):4889-96 - PubMed
  15. Genes Chromosomes Cancer. 2002 Mar;33(3):310-21 - PubMed
  16. Mol Carcinog. 2008 May;47(5):361-72 - PubMed
  17. Cell. 2000 Feb 18;100(4):423-34 - PubMed
  18. Genes Dev. 2010 Apr 1;24(7):670-82 - PubMed
  19. J Clin Invest. 1994 Jul;94(1):445-8 - PubMed
  20. Oncogene. 2007 Sep 27;26(44):6442-7 - PubMed
  21. Biochim Biophys Acta. 2010 Apr;1805(2):181-208 - PubMed
  22. Oncogene. 1999 Sep 20;18(38):5340-8 - PubMed
  23. Cancer Res. 2006 Oct 15;66(20):10171-8 - PubMed
  24. Medicine (Baltimore). 1987 Mar;66(2):98-113 - PubMed
  25. J Pathol. 2006 Jan;208(1):17-25 - PubMed
  26. Genes Chromosomes Cancer. 2000 Apr;27(4):337-44 - PubMed
  27. Genes Dev. 2008 Sep 15;22(18):2454-72 - PubMed
  28. N Engl J Med. 2009 Sep 17;361(12):1164-72 - PubMed
  29. Trends Pharmacol Sci. 2009 Jun;30(6):303-12 - PubMed
  30. Cancer Cell. 2008 Mar;13(3):249-60 - PubMed
  31. Genes Dev. 2009 Jan 1;23(1):24-36 - PubMed
  32. Nat Med. 1998 May;4(5):619-22 - PubMed
  33. FEBS Lett. 2009 Jan 5;583(1):224-8 - PubMed

Publication Types